Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Location Directory

Clinical trials in Indianapolis, Indiana

This page shows live ClinicalTrials.gov search results for Indianapolis, Indiana, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 7:04 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
8617
Shown on this page
12
Current sort
Recently updated
Location scope
Indianapolis, IN
Filters apply within this location only.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this location

These controls apply only within Indianapolis, Indiana. Default order is Recently updated. Use recruitment status if you want to focus on actively recruiting studies in this location.

Reset location filters
Clear filters
Showing 709–720 of 8,617 matching trials in Indianapolis, IN.
Live ClinicalTrials.gov results.
Local directory summary panels are hidden while filters are applied so the page stays focused on the filtered live results.

Live official records

Open in full search
Active, not recruiting Phase 3 Interventional

Research Study on Whether Semaglutide Works in People With Non-alcoholic Steatohepatitis (NASH)

NCT04822181
View directory record Official record
Conditions
Non-alcoholic Steatohepatitis
Interventions
Semaglutide, Placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
1,205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
130
States / cities
Huntsville, Alabama • Chandler, Arizona • Peoria, Arizona + 100 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Nov 15, 2026, 7:04 AM EST
Active, not recruiting Phase 1Phase 2 Interventional

S095035 as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of MTAP

NCT06188702
View directory record Official record
Conditions
MTAP-deleted Solid Tumors
Interventions
S095035, TNG462
Drug
Lead sponsor
Servier Bio-Innovation LLC
Industry
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
5
States / cities
Lake Mary, Florida • Indianapolis, Indiana • Maumee, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Nov 15, 2026, 7:04 AM EST
Recruiting Phase 3 Interventional

Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma

NCT06921785
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
Tremelimumab, Rilvegostomig, Bevacizumab, Atezolizumab
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
1,220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
37
States / cities
Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 31 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Nov 15, 2026, 7:04 AM EST
Recruiting Phase 3 Interventional

A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM

NCT07667803
View directory record Official record
Conditions
Weight Management
Interventions
Elecoglipron, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
4,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
56
States / cities
Birmingham, Alabama • Dothan, Alabama • Chandler, Arizona + 53 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Nov 15, 2026, 7:04 AM EST
Completed Not applicable Interventional

Nerve Protection Evaluation: Revision Cubital Tunnel Syndrome Decompression

NCT06117501
View directory record Official record
Conditions
Recurrent Cubital Tunnel Syndrome, Recalcitrant Cubital Tunnel Syndrome
Interventions
Axoguard HA+ Nerve Protector™
Device
Lead sponsor
Axogen Corporation
Industry
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
7
States / cities
Tampa, Florida • Savannah, Georgia • Indianapolis, Indiana + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Nov 15, 2026, 7:04 AM EST
Recruiting Phase 3 Interventional

Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function

NCT06307652
View directory record Official record
Conditions
Heart Failure and Impaired Kidney Function
Interventions
balcinrenone/dapagliflozin 15 mg/10 mg and matching placebo for dapagliflozin 10 mg, balcinrenone/dapagliflozin 40 mg/10 mg and matching placebo for dapagliflozin 10 mg, dapagliflozin 10 mg and matching placebo for balcinrenone/dapagliflozin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
3,850 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
166
States / cities
Alexander City, Alabama • Birmingham, Alabama • Fairhope, Alabama + 142 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Nov 15, 2026, 7:04 AM EST
Recruiting Phase 2 Interventional

SAFety and Efficacy of Human Anti-thymocyte ImmunoGlobUlin SAB-142 ARresting Progression of Type 1 Diabetes

NCT07187531
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
High Dose SAB-142, Low Dose SAB-142, Placebo
Drug · Other
Lead sponsor
SAb Biotherapeutics, Inc.
Industry
Eligibility
5 Years to 40 Years
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
22
States / cities
San Francisco, California • San Jose, California • Aurora, Colorado + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Nov 15, 2026, 7:04 AM EST
Completed Phase 3 Interventional

Open-Label Extension Study of DCCR in Patients With Prader-Willi Syndrome

NCT05701774
View directory record Official record
Conditions
Prader-Willi Syndrome
Interventions
DCCR
Drug
Lead sponsor
Soleno Therapeutics, Inc.
Industry
Eligibility
4 Years and older
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
17
States / cities
Orange, California • Palo Alto, California • San Diego, California + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Nov 15, 2026, 7:04 AM EST
Recruiting No phase listed Observational

Global Prospective, Observational Cohort of Adult Patients With Primary Sclerosing Cholangitis (WIND-PSC Study)

NCT06297993
View directory record Official record
Conditions
PSC
Interventions
Not listed
Lead sponsor
PSC Partners Seeking a Cure
Other
Eligibility
18 Years to 75 Years
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
11
States / cities
Sacramento, California • San Francisco, California • New Haven, Connecticut + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Nov 15, 2026, 7:04 AM EST
Completed Phase 3 Interventional

Study of Plozasiran in Adults With Severe Hypertriglyceridemia

NCT06347016
View directory record Official record
Conditions
Severe Hypertriglyceridemia
Interventions
Plozasiran Injection, Placebo
Drug
Lead sponsor
Arrowhead Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
311 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
50
States / cities
Birmingham, Alabama • Mobile, Alabama • Beverly Hills, California + 44 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Nov 15, 2026, 7:04 AM EST
Recruiting Phase 1 Interventional

Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors

NCT06276491
View directory record Official record
Conditions
Ovarian Cancer, Endometrial Cancer, Germ Cell Tumor, Testicular Germ Cell Tumor, Ovarian Germ Cell Tumor
Interventions
XmAb541
Biological
Lead sponsor
Xencor, Inc.
Industry
Eligibility
15 Years and older
Enrollment
282 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
17
States / cities
Duarte, California • Palo Alto, California • San Francisco, California + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Nov 15, 2026, 7:04 AM EST
Recruiting Phase 2 Interventional

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)

NCT06116682
View directory record Official record
Conditions
Lung Non-Small Cell Carcinoma
Interventions
Amivantamab, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging
Biological · Procedure
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
271
States / cities
Jonesboro, Arkansas • Little Rock, Arkansas • Auburn, California + 229 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Nov 15, 2026, 7:04 AM EST